AstraZeneca Seeks FDA Approval for Home Administration of FluMist Vaccine

If approved, self-administration of FluMist could increase vaccination rates by offering a convenient option for busy families and a needle-free alternative for those with needle phobia. Implementation could be in time for the 2024-25 flu season pending FDA approval expected in early 2024.

AstraZeneca applied to the U.S. FDA for approval of at-home self-administration of FluMist, the only needle-free flu vaccine available in the U.S., extending its use from administration by health professionals only.
The self-administration program would allow people ages 18-49 to administer the vaccine to themselves and to eligible children, after consultation with a medical professional and due fulfillment of storage requirements.
The self-administration of FluMist will be through pre-filled syringes ordered to homes via an online system, and is aimed at increasing vaccination rates by offering a convenient and needle-free alternative, especially to busy families and needle-phobic individuals.
FDA's decision on approval is expected during the first quarter of 2024 and if approved, the self-administration option would be ready for implementation by the 2024-2025 flu season.
AstraZeneca's application was bolstered with data from a 'usability study' showing that people could effectively self-administer the vaccine, drawing from the experience of home tests during the Covid-19 pandemic.